ZEN003694 + Enzalutamide
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-Resistant Prostate Cancer
Conditions
Metastatic Castration-Resistant Prostate Cancer
Trial Timeline
Sep 8, 2021 → Jun 1, 2026
NCT ID
NCT04986423About ZEN003694 + Enzalutamide
ZEN003694 + Enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Metastatic Castration-Resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04986423. Target conditions include Metastatic Castration-Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04986423 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metastatic Castration-Resistant Prostate Cancer